Seanergy Dermatology
Therapeutics for Atopic Dermatitis, Psoriasis, and Other Inflammatory Conditions
Company Overview
Snapshot
Founded in March 2018 by Eran Perry, Masanobu Ogawa, and Doron Friedman, Seanergy Dermatology operates with 1–10 employees. The company has secured funding across one round, with Maruho Israel Innovation Fund participating. In February 2020, the company received its initial funding.
Business overview
Seanergy Dermatology is a clinical-stage pharmaceutical company focused on developing topical therapeutics for inflammatory skin conditions such as Atopic Dermatitis and Psoriasis. The company's core technology is based on a patented discovery involving a synergistic mechanism between anti-inflammatory active pharmaceutical ingredients (APIs) and sulphated polysaccharides extracted from algae. Seanergy Dermatology operates within the Health Tech & Life Sciences sector, specifically targeting the Pharmaceuticals market with its drug discovery and development efforts.
Log in to access full profile ›Company Intelligence Q&A
- When was Seanergy Dermatology founded?
- Seanergy Dermatology was founded in March 2018.
- Who are the founders of Seanergy Dermatology?
- The founders of Seanergy Dermatology are Eran Perry, Masanobu Ogawa, and Doron Friedman.
- What is Seanergy Dermatology's primary focus?
- Seanergy Dermatology focuses on developing a new category of topical therapeutics for inflammatory skin conditions, including Atopic Dermatitis and Psoriasis.
- What is the core technology behind Seanergy Dermatology's products?
- The company's patented technology is based on a synergistic mechanism between anti-inflammatory APIs and sulphated polysaccharides extracted from algae.
- When did Seanergy Dermatology receive its first funding?
- Seanergy Dermatology received its first funding in February 2020, with participation from Maruho Israel Innovation Fund.